Navigation Links
Cardium Presents First Quarter 2012 Financial Results and Recent Developments
Date:5/15/2012

edicine, includes the Tissue Repair Company, Cardium Biologics, and the Company's in-house MedPodium Health Sciences healthy lifestyle product platform.  The Company's lead commercial product Excellagen™ topical gel for wound care management recently received FDA clearance for marketing and sale in the United States.  Cardium's lead clinical development product candidate Generx® is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease.  In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities.  In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio. News from Cardium is located at www.cardiumthx.com.

Forward-Looking Statements  

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from expectations. For example, there can be no assurance that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or in actual use; that new clinical studies will be successful or will lead to approvals or clearances from health regulatory authorities, or that approvals in one jurisdiction will help to support studies or approvals elsewhere; that the company can attract suitable commercialization partners for our products or that we or partners can successfully commercialize them; that our product or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effect
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Cardium to Present at Upcoming Investor Conferences
2. Cardiums Exchange Listing Compliance Plan Accepted by NYSE Amex
3. Cardium Reports Excellagen Matrix Clinical Study Results Accepted for Publication by Peer-Reviewed Journal, and Updates Product Plans
4. Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments
5. Cardium to Present at the LifeTech Capital Miami Medical Investors Conference
6. Cardium Gains Exclusive Access to Novel Polymer-Based Nitric Oxide Technology for Expansion of Wound Healing Product Portfolio
7. Cardium to Present at 10th Annual Biotech in Europe Investor Forum
8. Cardium Regains Listing Compliance With NYSE Amex
9. Cardium to Present at MDB Capital Groups 2010 Bright Lights Conference
10. Cardiums Exchange Listing Compliance Plan Accepted by NYSE AMEX
11. Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, ... focused on gynecologic disease, announced today that investors ... , Birchview Fund LLC and several Vermillion directors ... unregistered shares of Vermillion,s common stock and warrants ... in a private placement.  Under ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 /PRNewswire/ ... study of mazindol in children with attention deficit/hyperactivity disorder ... December 2014 . The paper, titled ... attention deficit/hyperactivity disorder" ( Konofal et al, ... eCollection 2014 ) shows that mazindol might be ...
(Date:12/22/2014)... 2014  Alternative Energy & Environmental Solutions, Inc., ... a letter of intent to acquire BioTechPharma Corporation, ... a nanotechnology-based development platform used to create drug ... on-site collection and testing to identify infectious disease, ... an immediate, non-invasive and cost-effective manner. ...
(Date:12/22/2014)... Chicago, Illinois (PRWEB) December 22, 2014 ... representing tenants and occupiers of commercial real estate, has ... two new offices in Perth and Brisbane, Western Australia, ... board of directors. , ITRA Global / ACORPP ... and totally independent consultancy company providing property services to ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3ALNE Announces Intention To Acquire BioTechPharma 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2
... 8 Arena Pharmaceuticals, Inc.,(Nasdaq: ARNA ) announced ... Bank of America 2008 Healthcare Conference on May 14, ... at the Four Seasons Hotel in Las,Vegas, Nevada. Dominic ... Officer, is scheduled to provide an overview of the,company, ...
... (NYSE: EW ), the world leader in the ... a number of cardiac surgery,milestones and product debuts at ... Surgery (AATS), May 10-14 in San Diego., Among ... celebrates,its 50th anniversary of partnering with clinicians to develop ...
... NEW YORK, May 8 Keryx Biopharmaceuticals,Inc. (Nasdaq: ... May 12, 2008 at,8:30 a.m. EDT to discuss the ... Chief Executive Officer of the Company, will host,the call. ... in a,press release to be issued prior to the ...
Cached Biology Technology:Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference 2Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference 3Edwards Lifesciences Celebrates One Million Heart Valve Patients and More at AATS 2008 2Edwards Lifesciences Celebrates One Million Heart Valve Patients and More at AATS 2008 3Edwards Lifesciences Celebrates One Million Heart Valve Patients and More at AATS 2008 4Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT 2
(Date:12/19/2014)... 2014   LaunchKey , the first decentralized mobile ... Internet of Things era, today announced the close of ... was led by Metamorphic Ventures with participation from ENIAC ... and others.  LaunchKey has raised $4 million to date, ... team and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has ... in the APAC Region 2015-2019"  report to their ... in this market is advances in technology. With ... upgrade biometric solutions to the latest standard that ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... for our brains and memory. But what is it about ... our memory sharper? Medical researchers at the University of ... in the peer-reviewed journal Applied Physiology, Nutrition, and Metabolism ... lab models fed a high-DHA diet had 30 per cent ...
... introduced to the U.S. for sale through plant nurseries, ... Although legislation restricts the introduction of certain species, the ... restricted list are haphazard and out of date. ... risk analysis, researchers at the University of Georgia Odum ...
... lines for American Idol demonstrate anything, it,s that people like ... audience, the better. Now researchers at Tel Aviv University have ... indigenous to Africa and the Middle East. According ... TAU,s Department of Zoology, hyrax vocalizations or "songs" go a ...
Cached Biology News:Screening horticultural imports: New models assess plant risk through better analysis 2Screening horticultural imports: New models assess plant risk through better analysis 3Looking for the next American hyrax? 2Looking for the next American hyrax? 3Looking for the next American hyrax? 4
Kit for BASE20/50 dual control unit, includes mounting plate, HOLDER50T, HEATERPAD50, SRTDX temperature probe(s)....
...
... R&D Systems Cell and Tissue Staining Kits ... a broad range of histological and cytological ... primary IgG antibodies manufactured by either R&D ... is based on the formation of the ...
... jetSI-ENDO is an easy-to-use siRNA transfection reagent ... endogenous genes in a variety of cell ... with an optimized, straightforward protocol. High levels ... obtained following transfection of 20 to 100 ...
Biology Products: